| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.071 | 0.3 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.059 | 0.3 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.3 |